About the Company
immunogen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics with its proprietary antibody-drug conjugate (adc) technology. the company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancers and other solid tumors. leading healthcare companies have licensed rights to use immunogen's technology to develop novel anticancer therapies, and roche's marketed product, kadcyla, utilizes immunogen's adc technology. more information about the company can be found at www.immunogen.com.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $IMGN News
Lazard posts first-quarter profit on deals, assets boost
Lazard reported a first-quarter profit on Thursday, compared with a loss a year earlier, buoyed by a growth in dealmaking and ...
ArriVent Appoints Kristine Peterson to its Board of Directors
“I am excited to work alongside ArriVent’s talented management team and Board of Directors to help address the unmet needs of cancer patients,” said Ms. Peterson. “I look forward to providing ...
Lazard profit beats estimates as dealmaking rebound fuels record revenue
Lazard's first-quarter profit exceeded estimates on Thursday, buoyed by a resurgence in dealmaking at the boutique investment ...
7 Billion-Dollar Oncology M&As from Q1
AbbVie’s $10.1 billion takeover of ImmunoGen paces the cancer sector in early 2024, as ADCs and radiopharmaceuticals remain ...
3 Potential Biopharma Buyout Targets
Drug blockbusters facing key patent expirations and Big Pharma's surplus of cash suggest increased M&A volume in the coming ...
Emergence of ADCs as the “hot, new technology”
The cycle from hot to cold to hot again can take 10-15 years and a new technology may go through more than one such cycle (as ...
GSK Sues Pfizer, BioNTech for Share of Billions in Vaccine Sales
GlaxoSmithKline filed a federal lawsuit seeking to recoup a share of the tens of billions of dollars in revenue Pfizer and ...
These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?
Dave has over 13 million registered members, 10 million of whom have used at least one product. It added over 680,000 new ...
Jefferies Hires Senior JPMorgan Health-Care Banker Philip Ross
Jefferies Financial Group Inc. has hired veteran health-care banker Philip Ross from JPMorgan Chase & Co., according to ...
Polaris Global Equity Composite Q1 2024 Commentary
Global equity markets enjoyed consecutive months of gains, with the MSCI World Index returning 9.01% for the quarter.
AbbVie gets grant for inhibitors of menin-MLL interaction for cancer treatment
Discover AbbVie Inc's groundbreaking patent for inhibitors targeting menin-MLL interaction in cancer treatment. Formula 0 compound offers hope for leukemia patients.
Acute Myeloid Leukemia Market Size is Expected to Grow by 2032 | DelveInsight
As per DelveInsight analysis, the Acute Myeloid Leukemia market is anticipated to witness growth at a considerable CAGR.
Loading the latest forecasts...